United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - tetrabenazine (unii: z9o08yrn8o) (tetrabenazine - unii:z9o08yrn8o) - tetrabenazine 12.5 mg - tetrabenazine tablets are indicated for the treatment of chorea associated with huntington's disease. tetrabenazine tablets are contraindicated in patients: risk summary there are no adequate data on the developmental risk associated with the use of tetrabenazine tablets in pregnant women. administration of tetrabenazine to rats throughout pregnancy and lactation resulted in an increase in stillbirths and postnatal offspring mortality. administration of a major human metabolite of tetrabenazine to rats during pregnancy or during pregnancy and lactation produced adverse effects on the developing fetus and offspring (increased mortality, decreased growth, and neurobehavioral and reproductive impairment). the adverse developmental effects of tetrabenazine and a major human metabolite of tetrabenazine in rats occurred at clinically relevant doses [see data] . in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15

United States - English - NLM (National Library of Medicine)

tagi pharma, inc. - tetrabenazine (unii: z9o08yrn8o) (tetrabenazine - unii:z9o08yrn8o) - tetrabenazine 12.5 mg - tetrabenazine tablet is indicated for the treatment of chorea associated with huntington's disease. tetrabenazine tablet is contraindicated in patients: risk summary there are no adequate data on the development risk associated with the use of tetrabenazine tablet in pregnant women. administration of tetrabenazine tablets to rats throughout pregnancy and lactation resulted in an increase in stillbirths and postnatal offsprings mortality. administration of major human metabolite of tetrabenazine to rats during pregnancy or during pregnancy and lactation produced adverse effects on developing fetus and offspring (increased mortality, decreased growth and neurobehavioral and reproductive impairment). the adverse development effects of tetrabenazine and a major human metabolite of tetrabenazine in rats occurred at clinically relevant doses [see data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 % and 15 to 20%,

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

handok inc. - glimepiride, metformin (metformin hydrochloride) - tablets film-coated - 2mg+500mg

Ireland - English - HPRA (Health Products Regulatory Authority)

valeant pharma poland sp. z o.o. - tetrabenazine - tablet - 25 milligram(s) - other nervous system drugs; tetrabenazine

Ireland - English - HPRA (Health Products Regulatory Authority)

bausch health ireland limited - tetrabenazine - tablet - 25 milligram(s) - other nervous system drugs; tetrabenazine

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - tetrabenazine (unii: z9o08yrn8o) (tetrabenazine - unii:z9o08yrn8o) - tetrabenazine tablets are indicated for the treatment of chorea associated with huntington’s disease. tetrabenazine is contraindicated in patients: risk summary there are no adequate data on the developmental risk associated with the use of tetrabenazine in pregnant women. administration of tetrabenazine to rats throughout pregnancy and lactation resulted in an increase in stillbirths and postnatal offspring mortality. administration of a major human metabolite of tetrabenazine to rats during pregnancy or during pregnancy and lactation produced adverse effects on the developing fetus and offspring (increased mortality, decreased growth, and neurobehavioral and reproductive impairment). the adverse developmental effects of tetrabenazine and a major human metabolite of tetrabenazine in rats occurred at clinically relevant doses [see data] . in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectiv

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

handok inc. - glimepiride, metformin (metformin hydrochloride) - tablets prolonged-release - 2mg+ 500mg

United States - English - NLM (National Library of Medicine)

slate run pharmaceuticals, llc - tetrabenazine (unii: z9o08yrn8o) (tetrabenazine - unii:z9o08yrn8o) - tetrabenazine tablets are indicated for the treatment of chorea associated with huntington’s disease. tetrabenazine tablets are contraindicated in patients: risk summary there are no adequate data on the developmental risk associated with the use of tetrabenazine tablets in pregnant women. administration of tetrabenazine to rats throughout pregnancy and lactation resulted in an increase in stillbirths and postnatal offspring mortality. administration of a major human metabolite of tetrabenazine to rats during pregnancy or during pregnancy and lactation produced adverse effects on the developing fetus and offspring (increased mortality, decreased growth, and neurobehavioral and reproductive impairment). the adverse developmental effects of tetrabenazine and a major human metabolite of tetrabenazine in rats occurred at clinically relevant doses [see data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 t

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

handok inc. - glimepiride, metformin (metformin hydrochloride) - tablets film-coated - 2mg+ 500mg

Ireland - English - HPRA (Health Products Regulatory Authority)

aop orphan pharmaceuticals gmbh - tetrabenazine - tablet - 25 milligram(s) - other nervous system drugs; tetrabenazine